Although we did not assess the possibility for TGF-β3 to be used as a prognostic biomaker or target, analysis of the TCGA data by Seystahl and collaborators revealed that low expression of this isoform was associated with a better prognosis in GBM of the neural subtype whereas it bore no significant effect in proneural, mesenchymal, or classical GBM subtypes. Here, TGFB3 is linked to glioblastoma.